These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 27143132)
21. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. Imesch P; Dedes KJ; Furlato M; Fink D; Fedier A Int J Oncol; 2009 Sep; 35(3):631-40. PubMed ID: 19639184 [TBL] [Abstract][Full Text] [Related]
22. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents. Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008 [TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors. Tashima T; Murata H; Kodama H Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038 [TBL] [Abstract][Full Text] [Related]
24. Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents. Mahal K; Schruefer S; Steinemann G; Rausch F; Schobert R; Biersack B; Höpfner M Cancer Chemother Pharmacol; 2015 Apr; 75(4):691-700. PubMed ID: 25618416 [TBL] [Abstract][Full Text] [Related]
25. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors. Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326 [TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors. Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621 [TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents. Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133 [TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent. Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839 [TBL] [Abstract][Full Text] [Related]
29. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Xu WS; Perez G; Ngo L; Gui CY; Marks PA Cancer Res; 2005 Sep; 65(17):7832-9. PubMed ID: 16140952 [TBL] [Abstract][Full Text] [Related]
30. Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA. Bressan A; Bigioni M; Bellarosa D; Nardelli F; Irrissuto C; Maggi CA; Binaschi M Oncol Rep; 2010 Nov; 24(5):1249-55. PubMed ID: 20878117 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors. Huang WJ; Chen CC; Chao SW; Yu CC; Yang CY; Guh JH; Lin YC; Kuo CI; Yang P; Chang CI Eur J Med Chem; 2011 Sep; 46(9):4042-9. PubMed ID: 21712146 [TBL] [Abstract][Full Text] [Related]
32. New aryldithiolethione derivatives as potent histone deacetylase inhibitors. Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572 [TBL] [Abstract][Full Text] [Related]
33. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. Bieliauskas AV; Weerasinghe SV; Pflum MK Bioorg Med Chem Lett; 2007 Apr; 17(8):2216-9. PubMed ID: 17307359 [TBL] [Abstract][Full Text] [Related]
34. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase. Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563 [TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors. Liu R; Wang J; Tang W; Fang H Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204 [TBL] [Abstract][Full Text] [Related]
36. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
37. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. Chen L; Wilson D; Jayaram HN; Pankiewicz KW J Med Chem; 2007 Dec; 50(26):6685-91. PubMed ID: 18038969 [TBL] [Abstract][Full Text] [Related]
38. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases. Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250 [TBL] [Abstract][Full Text] [Related]
39. Identification of an epigenetic signature of early mouse liver regeneration that is disrupted by Zn-HDAC inhibition. Huang J; Schriefer AE; Yang W; Cliften PF; Rudnick DA Epigenetics; 2014 Nov; 9(11):1521-31. PubMed ID: 25482284 [TBL] [Abstract][Full Text] [Related]